home
journals
ADHD in practice
British Journal of Renal Medicine
British Journal of Sexual Medicine
Clinical issues in HIV
Dermatology in practice
European Journal of Palliative Care
Managing pain in practice
Myeloid & Lymphoid disorders in practice
Ophthalmology in practice
Respiratory disease in practice
Rheumatology in practice
Thrombus
Vaccines in practice
Viral hepatitis in practice
editorial boards
ADHD in practice
British Journal of Renal Medicine
British Journal of Sexual Medicine
Dermatology in practice
European Journal of Palliative Care
Managing pain in practice
Myeloid & Lymphoid disorders in practice
Ophthalmology in practice
Respiratory disease in practice
Rheumatology in practice
Thrombus
Vaccines in practice
Viral hepatitis in practice
what is …? series
login
Thrombus - 2007
Winter 2007, Volume 11 Number 4
Autumn 2007, Volume 11 Number 3
Role of the
JAK2
mutation in abdominal vein thrombosis
Catherine N Bagot, Raj K Patel and Roopen Arya
pp 1-3
Venous thrombosis in the portal, mesenteric and hepatic veins are rare but severe conditions often affecting young patients. Thrombosis of the hepatic veins results in Budd–Chiari syndrome (BCS), which has a heterogeneous clinical presentation. Portal vein thrombosis (PVT) presents with complications of portal hypertension. Extension of thrombosis into the mesenteric veins may cause intestinal infarction. Mortality rates are 5–38% (BCS) and 10–25% (PVT), with prognosis highly dependent on patient age at presentation and the underlying aetiology of the thrombotic event. Diagnosis is by Doppler ultrasonography, computerised tomography (CT) (see Figure 1) or MRI.
Comment: Look and learn
David Fitzmaurice and Ellen Murray
pp 2-2
The last 20 years have seen a revolution in service delivery for patients receiving oral anticoagulation therapy, principally warfarin, in the UK. The main driver for this revolution has been the increasing number of patients with atrial fibrillation who are receiving warfarin as thromboprophylaxis. There is compelling evidence for the use of warfarin in atrial fibrillation, with a reduction in stroke rates of about 60% and a reduction in mortality of about 40%.
Predicting the recurrence of thrombosis
Ian Jennings
pp 4-5
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the Western world, with an annual incidence in the general population estimated to be 1:1,000. A number of factors, both inherited and acquired, are known to increase the risk of thrombosis (see Table 1). Predicting a first thrombotic event in asymptomatic individuals is problematic. Population screening for thrombophilia cannot be justified on the grounds of cost or clinical utility.
Obesity and venous thromboembolism
Vikramajit Singh, Paneesha Shankaranarayana and Peter Rose
pp 6-7
In 1856, Rudolph Virchow identified three primary risk factors – classically described as Virchow’s triad – for venous thromboembolism (VTE): venous stasis, hypercoagulability, and endothelial injury. Since then, many other risk factors have been identified. The magnitude of these vary, and the independence of each is, at best, uncertain. Table 1 lists both major and minor risk factors.
Resistance to antiplatelet agents
Paul Harrison
pp 8-11
As platelets are firmly implicated in the pathology of atherosclerosis and arterial thrombosis, antiplatelet therapy forms an important and effective component of both treatment and prophylactic strategies.1 Many established antiplatelet drugs are traditionally administered at standard doses without monitoring of their efficacy.
Summer 2007, Volume 11 Number 2
Spring 2007, Volume 11 Number 1
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy